Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 367 Next >>

Filter Applied: cerebrovascular accident,prevention of (Click to remove)

Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention
Neurol 94:876-885, Messe, S.R.,et al, 2020

Implantable Cardiac Monitoring in the Secondary Prevention of Cryptogenic Stroke
Ann Neurol 88:946-955, Triantafyllou, S.,et al, 2020

Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
NEJM 380:1906-1917, Diener, H.C.,et al, 2019

Patent Foramen Ovale Closure, Antiplatelet Therapy or Anticoagulation Therapy Alone for Management of Cryptogenic Stroke?
BMJ 362:k2515, Kuijpers, T.,et al, 2018

Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
NEJM 377:1022-1032,1006,1093, Saver, J.L.,et al, 2017

Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017

Closure Versus Medical Therapy for Preventing Recurrent Stroke in Patients with Patent Foramen Ovale and a History of Cryptogenic Stroke or Transient Ischemic Attack
Stroke 47:e188-e189, Li, J.,et al, 2016

Primary Prevention of Stroke
JAMA 316:658-659, Steiger, N. & Cifu, A.S., 2016

The Value of Transesophageal Echocardiography for Embolic Strokes of Undetermined Source
Neuol 87:988-995, Katsanos, A.H.,et al, 2016

Summary of Evidence-Based Guideline Update: Prevention of Stroke in Nonvalvular Atrial Fibrillation
Neurol 82:716-724, Culebras, A.,et al, 2014

Cryptogenic Stroke and Underlying Atrial Fibrillation
NEJM 370:2478-2486,2532, Sanna, T.,et al, 2014

Atrial Fibrillation in Patients with Cryptogenic Stroke
NEJM 370:2467-2477,2532, Gladstone, D.J.,et al, 2014

Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013

Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013

Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention
Stroke 43:422-431, Kitsios,G.D.,et al, 2012

Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
NEJM 366:991-999,1048, Furlan,A.J.,et al, 2012

Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:227-276, Furie,K.L.,et al, 2011

Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes
Stroke 40:1405-1409, Amarenco,P.,et al, 2009

Stroke
Lancet 371:1612-1623, Donnan,G.A.,et al, 2008

Therapeutic Strategies After Examination by Transesophageal Echocardiography in 503 Patients with Ischemic Stroke
Stroke 37:859-864, Harloff,A.,et al, 2006

Should I Start All My Ischaemic Stroke and TIA Patients on a Statin, an ACE Inhibitor, a Diuretic, and Aspirin Today?
JNNP 74:1461-1464, Sandercock,P.A.G., 2003

Prognostic Importance of Leukoaraiosis in Patients with Symptomatic Internal Carotid Artery Stenosis
Stroke 33:1651-1655, Streifler,J.Y.,et al, 2002

Should Stroke Subtype Influence Anticoagulation Decisions to Prevent Recurrence in Stroke Patients with Atrial Fibrillation?
Stroke 32:2828-2832, Evans,A.,et al, 2001

Importance of Hemodynamic Factors in the Prognosis of Symptomatic Carotid Occlusion
JAMA 280:1055-1060, 10931998., Grubb,R.L.,et al, 1998

Lipids and Stroke
Arch Neurol 53:303-308, Hachinski,V.,et al, 1996

Cost-Effectiveness of Warfarin and Aspirin for Prophylaxis of Stroke in Patients with Nonvalvular Atrial Fibrillation
JAMA 274:1839-1845, Gage,B.F.,et al, 1995

Transient Ischemic Attacks and Minor Stroke During Sleep:Relationship to Obstructive Sleep Apnea Syndrome
Stroke 26:2361-2365, Pressman,M.R.,et al, 1995

Medical Treatment for Stroke Prevention
Ann Int Med 121:41-55, Matchar,D.B.,et al, 1994

Predictors of Thromboembolism in Atrial Fibrillation:I. Clinical Features of patients at Risk
The Stroke Prevention in A Fib Investigators, Ann Int Med 116:1-51992., , 1992

Atrial Fibrillation as an Independent Risk Factor for Stroke:The Framingham Study
Stroke 22:983-988, Wolf,P.A.,et al, 1991

Antiphospholipid Antibodies in Cerebral Ischemia
Stroke 22:750-753, Montalban,J.,et al, 1991

The Effect of Low-Dose Warfarin on the Risk of Stroke in Patients with Nonrheumatic Atrial Fibrillation
NEJM 323:1505-1511, 1556-15581990., Kistler,J.P.,et al, 1990

Stroke-1989 Recommendations on Stroke Prevention
Diagnosis, and Therapy, Report of the WHO Force on Stroke and CV Disorders, Stroke 20:1407-143189., , 1989

Controversies in the Management of Cerebral Vascular Disease
Neurol 38:1609-1616, Scheinberg,P., 1988

Asundexian for Secondary Stroke Prevention
NEJM 394:1467-1479, 1540, Sharm,M.,et al, 2026

Collaboration on the Optimal Timing of Anticoagulation after Ischaemic Stroke and Atrial Fibrillation:A Systematic Review and Prospective Individual Participant Data Meta-Analysis of Randomised Controlled Trials (CATALYST)
Lancet 406:43-51, Dehbi,K-M.,et al, 2025

Apixaban vs Aspirin in Patients with Cancer and Cryptogenic Stroke A Post Hoc Analysis of the ARCADIA Randomized Clinical Trial
JAMA Neurol 81:957-965, Navi,B.B.,et al, 2024

Optimal Timing of Anticoagulation after Acute Ischaemic Stroke with Atrial Fibrillation (OPTIMAS): A Multicentre, Blinded-Endpoint, Phase 4, Randomised Controlled Trial
Lancet 404:1731-1741, Werring,D.J.,et al, 2024

2024 Guide for the Primary Prevention of Stroke:A Guideline From the American Heart Association/American Stroke Association
Stroke 55:e344-e424, Bushnell,C.,et al, 2024

Diagnosis, Workup, Risk Reduction of Transient Ischemic Attack in the Emergency Department Setting:A Scientific Statement From the American HEart Association
Stroke 54:e109-e121, Hardik,P.A.,et al, 2023

Dual Antiplatelet Treatment up to 72 Hours After Ischemic Stroke
NEJM 389:2413-2424, 2478, Gao,Y.et al, 2023

Bleeding Risk of Dual Antiplatelet Therapy after Minor Stroke or Transient Ischemic Attack
Ann Neurol 91:380-388, Wang, A.,et al, 2022

Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory
Neurol 98:486-498, Turan, T.N.,et al, 2022

A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
NEJM 382:9-19,81, Amarenco, P.,et al, 2020

Use of Dual Antiplatelet Therapy Following Ischemic Stroke
Stroke 51:e78-e80, Dong, J.,et al, 2020

Antiplatelet Treatment to Prevent Early Recurrent Stroke
NEJM 383:276-278, Rothwell, P.M., 2020

Antiplatelet and Anticoagulant Agents for Secondary Prevention of Thromboembolic Events in People with Antiphospholipid Syndrome
Stroke 49:e41-e42, Bala, M.M.,et al, 2018

Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies
BMJ 360:k1717, Adderley, N.J.,et al, 2018

Diagnosis and Management of Active Intracranial Atherosclerotic Disease
Stroke 49:e221-e223, Narwal, P.,et al, 2018



Showing articles 0 to 50 of 367 Next >>